Greenwich Biosciences

Description

• Greenwich Biosciences' vision is to make a positive difference in the lives of patients through the development of a portfolio of cannabinoid prescription medicines in a wide range of therapeutic indications. Our strategy is to build on our world leading position in the field of cannabinoid science and in the research, development and commercialization of cannabinoid molecules as novel prescription pharmaceutical therapeutic candidates. Epidiolex is Greenwichs lead cannabinoid product candidate and is a proprietary oral solution of pure plant-derived cannabidiol, or CBD. Greenwichs Epidiolex development is initially concentrating on severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS).We have made a commitment to establish a fully integrated US operation to commercialize the product, with our US headquarters in Carlsbad, CA. Our Parent company (GW Pharmaceuticals, PLC), was founded in 1998 and is based in the UK. We are continuing to build out our team and are looking for talented individuals dedicated to making a difference in the lives of our patients.
• 

  Headquarters:5800 Armada Dr Ste 210 5800 Armada Drive, Suite 210, Carlsbad, California, United States

  More
• 

  Phone Number: +1 760-795-2200

• 

  Website: gwpharm.com

• 

  Employees:1011

• 

  Revenue:$250 - 500M

• 

  Legal Name:Greenwich Biosciences

• Greenwich Biosciences's Social Media

  
• Is this data correct?

• |  NAICS Code: 325412  |

  Show More